Metabical Case

In: Religion Topics

Submitted By reinathaniel
Words 564
Pages 3
Reinald Nathaniel 29115153 – Syndicate 1
Metabical Case
According to the data and our calculation, there are two methods that could be used to be consider in Metabical’s pricing strategy. First we would narrow the population into a niche market by filtering the numbers. It is done by taking the number of people who tries to lose weight, then the next filter that we put is: to sort out by the number of people who are comfortable in using pills (Method 1). The other method is to get the number from people who wants to consume drugs with prescription (Method 2). Year | Americanswith 25>BMI>30 | Population Trying to Lose Weight (35%) | Comfortable using diet pills (15%) | Medibical Will Capture | Population Captured | Sales | 1 | 71,060,000 | 24,871,000 | 3,730,650 | 10% | 373,065 | 37,300,381.73 | 2 | 71,060,000 | 24,871,000 | 3,730,650 | 15% | 559,598 | 55,950,572.60 | 3 | 71,060,000 | 24,871,000 | 3,730,650 | 20% | 746,130 | 74,600,763.47 | 4 | 71,060,000 | 24,871,000 | 3,730,650 | 25% | 932,663 | 93,250,954.34 | 5 | 71,060,000 | 24,871,000 | 3,730,650 | 30% | 1,119,195 | 111,901,145.20 | | Total sales | 373,003,817.34 | | Total Investment | 488,730,000 | | ROI | -23.68% |
METHOD 1:

Total investment (marketing costs, manufacturing overhead $ 1.2 million per year, R&D with sunk cost $400 million).
ROI = (total sales-total investment)total invesmentx 100%
METHOD 2: Year | Americanswith 25>BMI>30(34% overweight) | Population gotothedoctortorequestprescription (12%) | Medibical Will Capture | Population Captured | Sales | 1 | 71,060,000 | 8,527,200 | 10% | 373,065 | 85,258,015.39 | 2 | 71,060,000 | 8,527,200 | 15% | 559,598 | 127,887,023.09 | 3 | 71,060,000 | 8,527,200 | 20% | 746,130 | 170,516,030.78 | 4 | 71,060,000 | 8,527,200 | 25% | 932,663 | 213,145,038.48 | 5 | 71,060,000 | 8,527,200 | 30% | 1,119,195 |…...

Similar Documents

Metabical

...scheme given in the case can be broadly classified into demographic and psychographic - Demographic(age, gender, family size, lifecycle, income, religion)- 1. BMI - Broadly over Answer 3 1st Basis of Segmentation is BMI 34% of people 2nd Basis of Segmentation - Gender As per exibit 1, 67% of Men and 62% of Women are in Now to further get a segmentation we went back to exhibit 2. Points 5 to point 9 tell us that women is what we need to target. 3rd Basis of segmentation is education 3rd last point of exhbit 2, 75% with college degree are aware of health risks associated with being overweight. 4th Basis of segmentation - psychographic (Page 78) - when a psychographic analysis was carried out, 'I want to be healthier' is the kind of proposition Metabical wants to make. It is a healthy drug, better than its predecessors, going to be FDA approved. Thus, this is the target audience we expect to be drawn to us and stick with us. Thus, as per Page 78, the group corresponding to this tagline - 35-65, college education plus, household income $80,000+ As on Page 78, we want to go with target group no. 2 i.e. the one who abide by the tagline 'I want to be healthier'. Metabical is a healthy drug. It promises to be better than its predecessors, it has less side effects and will be FDA approved soon. So, it looks for consumers who value health benefits and make that the cause of wanting to do something about their weight. Metabical looks for......

Words: 701 - Pages: 3

Metabical Case Solutions

...Weeden, Jason Giest, Kerri Kuhn Group 12 Metabical Case Current Competition Metabical is the “first and only prescription weight loss drug to receive FDA approval.” This prescription drug has less side affects than current weight loss options, which creates a market niche because if people are not obese but want to lose 10-30 pounds they might consider it if the negative affects are subtle. CSP is targeting overweight people (BMI between 25 and 30) not obese or sever obese people (BMI >30 or BMI >40), which is different from other weight loss drugs. They were able to do this by combining the “2 categories of prescription diet drugs: appetite suppressants and fat-absorbing blockers” in a dual layer pill. “The first layer contained an appetite suppressant, calosera, while the second layer contained a fat blocker and calorie absorption agent, meditonan.” These drugs worked in low dose levels, which created less negative affect on the body. Prescription drugs often have side effects but Metabical has no side effects associated with it, which is another major selling point for CSP. Some of the side effects listed for Metabical’s competition were serious enough to cause long term damage such as liver failure, kidney stones, severe stomach pain and gallbladder disease. Some of the major side effects were even life threatening. Not killing the customer is always a good strategy and encourages repeat business. The formula used for Metabical is also an advantage, the......

Words: 1464 - Pages: 6

Metabical

...------------------------------------------------- 1. ¿Cómo se compara Metabical con las actuales opciones de pérdida de peso? Es un medicamento por prescripción médica que se concentra en un nicho de mercado, que son las personas que quieren perder peso en forma moderada. No está prometiendo que atacara la obesidad se enfoca en tratar desordenes metabólicos. Además está ofreciendo ser el medicamento que validada por la FDA y ocasiones daños o efectos secundarios pequeños, y no está dirigido en una persona con altos niveles de obesidad, como ha pasado con la otras soluciones del mercado, Que no son validados por la FDA y que son clasificados como suplementos alimenticios. Metabical, será el primero en su ramo de medicamentos ya que está diseñado para gente con un índice de masa muscular entre 25 y 30 (sobre peso) aprobado por la FDA ya que para estos rangos no existe ningún tipo de medicamento, todos estaban enfocados a Obesidad y Obesidad Extrema entre 30 y 40 de índice de masa muscular; los medicamentos de los rangos altos (Sibutramina y Orlistat), han presentado con contraindicaciones importantes de hígado y vesícula por lo cual solo estaban autorizados a un rango distinto de Índice de masa muscular. Este será un medicamento que ataque dos puntos al suprimir el apetito por un lado y por otro contará con un bloqueador de absorción de grasa. Meta bical ha dado resultados en 12 semanas perdiendo las personas de 10 a 30 libras. Se estima que además de enfocarse a la......

Words: 1473 - Pages: 6

Metabical

...Problem statement Pricing must be decided for Metabical that captures the accurately forecasted demand of the target market. Because of heavy competition such as Alli , it is important to create a package that can be priced accurately to drive up sales and consistency of a 12 week drug. Situation Analysis Cambridge Sciences Pharmaceuticals’ (CSP) is international health care company. Their focus is on developing, manufacturing and marketing products that treat various diseases. They want to enter the market for weight-control products in the US. Metabical was part of a strategic initiative that allows CSP to enter $3.74 billion market for weight control products in the United States. Metabical’s competitors are Alli and Xenical and are FDA approved. In utilizing the SWOT analysis, it was determined Metabical had positive results in the clinical trials and is decent in comparison to other competitors in the market place. It also has dual layer controlled release formulation. Opportunities for this product would be a potential large market, constant rise of obese adults and a substitute for other weight loss methods. “In principle, Metabical would be attractive to all overweight individuals” however, Barbara Printup established a more focused plan of approach: First, the approach completed by Printup is the forecasted demand by considering the number of overweight individuals in the United States and focusing down that population to those who were actively trying to......

Words: 984 - Pages: 4

Metabical

...eport abuse Transcript of Metabical Case Study Presented by: The Lever Group Metabical - Case Study Goal? Targeting and Positioning: How to market Metabical to the correct audience to maximize sales Who are we? The Lever Group An independent market research group specializing in the balance between exercise and diet for overweight individuals Cambridge Sciences Pharmaceuticals (CSP) International health care company $25 billion in sales in 2007 Makers of Zimistat Metabical - may be first FDA approved prescription drug? Shown to be very effective for slightly overweight individuals The Situation Ideal target customer is a slightly overweight female between the age of 35-65. Positioning Strategy Losing weight is tough. You don't have to do it alone. Let Metabical and your health care provider start you on the road to a healthy weight and better life. (End Consumers) Advertising Message How to Market? TARGET: SWOT ANALYSIS CSP has spent 10 years and $400 million developing Metabical A successful launch will ensure a steady, long-term demand. Not a long term solution for patients Should be combined with diet and exercise Emphasize support program to change behavior patterns with over-eating The Consumer Decision Making Process Empower your patients to lose excess weight, change their unhealthy eating habits, and achieve long term success. Introducing Metabical – short-term drug therapy and a comprehensive support program for overweight patients. It gets......

Words: 342 - Pages: 2

Metabical

...Metabical: Pricing, Packaging, and Demand Forecasting for a New Weight-Loss Drug 1- Discuss Metabical’s points of differentiation compared to current weight-loss options? After 10 years of testing and spending a significant amount in research and development. Cambridge Sciences Pharmaceuticals (CSP) discovered one of the best weight- loss drug that called Metabical. Metabical has unique characteristics that make it different in market. People are always concerned about the side effect of any drug and sometime they preclude taking drug just because they are doubtful. Metabicals is differentiated by the Food and Drug Administration (FDA) approval. It is the first and only prescription drug that received FDA approval to meet the needs of consumer. Negative side effects disgrace many previous prescription weight loss drugs and most people become more cautious of using any weight loss drugs. While, metabicals has very minor side effects, it becomes the optimum option to who are concerned about the negative consequences. Metabicals gained consumers’ confidence who are looking to effective method to reach a desirable weight and improve their overall health. Metabical effectiveness is one of the keys that drive the product to success. The study shows people who are taking Metabical loss an average of 26 pounds, while other who is using a placebo loss an average of 6 pounds. One of the differences is Metabical maintained weight loss levels within 10% of the clinical......

Words: 3129 - Pages: 13

Metabical

...------------------------------------------------- CASE STUDY N°1 I. Introduction Cambridge Sciences Pharmaceuticals (CSP) is an international health care company that focus on developing, manufacturing, and marketing products that treat metabolic disorders, gastrointestinal diseases, imm une deficiencies, and other chronic and acute medical conditions. The company captured over $25 billion in sales in 2007. CSP created Metabical, what would be the first prescription drug approved by the FDA specifically for overweight individuals (those with a BMI of 25 to 30). Its compounds produce dramatic weight loss for overweight individuals. It works on a low-dose formulation, therefore reducing damages to heart and liver functions. Negative effects of the drug occurred when taken while consuming high levels of calories and fat. Metabical is intended to be taken during a 12-week treatment. The estimated retail price for the drug would be approximately $3 to $5 per day, so that would sum up to $1,800. Many health care insurance companies don’t cover weight-loss drugs in their plans. Direct competition includes over-the-counter (OTC) drug Alli (a reduced-strength version of the prescription drug Xenical), approved by the FDA for weight-loss use. There are a number of liver damage reports of people who have been taking Alli and Xenical being currently investigated by the FDA. Because of its recommended intake treatment, Metabical helps with behavior modification and......

Words: 2159 - Pages: 9

Metabical

...Metabical: Pricing, Packaging &Demand Forecasting For A New Weight Loss Drug Metabical: Pricing, Packaging &Demand Forecasting For A New Weight Loss Drug Abstract Metabical will be the only weight loss drug clinically proven to be effective for moderately overweight people, also recognized by the FDA. The CSP’s (Cambridge Sciences Pharmaceuticals) drug Metabical got its final approval from the FDA. The senior marketing director for CSP-Barbara Printup must develop the marketing communication and positioning strategy for a successful launch of the new drug Metabical. The main points to be stressed on by Barbara are consumer decision making concept and understanding between the consumer who is purchasing the drug and the health care provider who prescribes the medicine. Poor positioning of the drug in a highly competitive market for weight loss solutions could prove to be disastrous despite promising medical studies and consumer research. CSP wanted to base their new product comparably to Alli, but felt Metabical could be priced at a premium due to the need of a prescription to get the drug. Pricing was the main concern with this product and several scenarios were run to try and project and forecast where the pricing would give the best returns on investment. Objective * Develop Positioning Strategy for the drug. * Build the marketing communication plan in order to create a strong level of understanding between the consumer and the prescriber of the......

Words: 671 - Pages: 3

Metabical

...METABICAL CASE ANALYSIS Metabical is a prescription drug produced by Cambridge Sciences Pharmaceuticals (CSP) for weight loss, which was the first and only prescription drug to obtain FDA approval. The drug was developed to help aid people in the overweight segment to lose 10 to 30 pounds. Barbara Printup is the marketing director in charge of selecting a price for the new prescription drug. In a study CSP did with Metabical, people with a body mass index (BMI) of 28 to 30 had an average weight loss of 26 pounds over a 12 week period. At the same time, people with a BMI of 25-28 had an average weight loss of 15 pounds. This study found the new prescription drug to be useful and effective. Through research, Printup decided to target female consumers in the 35 to 65 age range with a college education. Metabical was also basing pricing and packaging compared to their main competitors in this particular market. CSP wanted to base their new product comparable to Alli, but felt Metabical could be priced at a premium due to the need of a prescription to get the drug, and the fact that they were the only FDA approved weight loss drug on the market. Pricing was a main concern with this product and several scenarios were run to try and project and forecast where the pricing would make the best return on investment (ROI). In order for the drug to be able to show positive results it is recommended that it should be taken daily for 12 weeks, without a single miss just like birth......

Words: 819 - Pages: 4

Metabical

...METABICAL In this case, Cambridge Sciences Pharmaceuticals (CSP) developed a new weight-loss drug named Metabical. In order to manufacture Metabical and launch it into market successfully, CSP had made market research, product experiment, and market communications strategy. Based on my analysis, CSP’s plan should be a medium risk strategy. The reasons were, it would be a little difficult to target the right customers in overweight segmentation, and people did not have any measuring standards for Metabical. The first reason was it would be a little difficult to target the right customers in overweight segmentation. Metabical was the first prescription drug which targeted at overweight group. Before Metabical was developed, there was no drug for the Body Mass Index (BMI) between 25 and 30 (Gonzalez, 2014, p. 25). Until CSP noticed in this segment that would be a potential market, then they advanced Metabical. But there were different preference customers in the overweight group which could divide by age, gender, psychographic data and educational level. In other words, if CSP wanted to locate the right customers accurately, it would have to do amount market surveys. The second reason was people did not have any measuring standards for Metabical, which indicated they were not familiar with this new product that might lead people not to trust Metabical at the first place. To build credibility and good reputation always......

Words: 375 - Pages: 2

Metabical  Business Case

...Pharmaceuticals’ (CSP) newest prescription drug, Metabical. CSP was an international healthcare company with over $25 billion in sales in 2007. Metabical was part of a strategic initiative that would allow CSP to enter the $3.74 billion market for weight-control products in the United States (7). Metabical was target as a prescription (Rx) for use by those looking to shed between 10 to 30 pounds. Initial reviews from the medical community indicate a strong endorsement of Metabical. It should offer moderately overweight adults a medically proven, effective method to reach a desirable weight and improve their overall health. The majority of Metabical trials participants reached their weight-loss goals by week 12. Although pricing had not been finalized, CSP estimated the retail price for the drug would be approximately $3 to $5 per day, with the average course treatment lasting 12 weeks. The primary question in this case is to analyze the market survey done by the company regarding overweight issues in order for us to decide which is the best market segmentation should be target. The second focus in this report is to position the best strategy which we will state the point of parity and point of differences of Metabical and come out with the positioning strategy and target market. The third focus will be the the SWOT analysis of the product which we will state the strengths, weaknesses, opportunities, and threats of Metabical which lead us indeciding which marketing......

Words: 1641 - Pages: 7

Metabical-Case Study

...yo Metabical: Pricing, Packaging, and Demand Forecasting for a New Weight-Loss Drug In April 2008, after 10 years of testing and $400 million in research and development costs, Cambridge Sciences Pharmaceuticals’ (CSP) newest prescription drug, Metabical (pronounced Mehtuh-bye-cal), was about to receive its coveted Food and Drug Administration (FDA) approval. CSP was an international healthcare company with over $25 billion in sales in 2007. The company, based in Cambridge, Massachusetts, focused on developing, manufacturing, and marketing products that treated metabolic disorders, gastrointestinal diseases, and immune deficiencies, as well as other chronic and acute medical conditions. Metabical was part of a strategic initiative that would allow CSP to enter the $3.74 billion market for weight-control products in the United States.1 tC CSP’s chief marketing officer, Bernard Long, said of the new product: No Metabical is revolutionary. It will be the first and only prescription drug to receive FDA approval to meet the needs of the millions of individuals struggling with moderate weight-loss goals. Previous prescription weight-loss drugs had negative side effects that, in the agency’s judgment, outweighed the benefits provided to individuals who were not considered obese. Metabical will be approved for use by those looking to shed between 10 to 30 pounds. Initial reviews from the medical community indicate a strong endorsement of Metabical. Our......

Words: 4511 - Pages: 19

Metabical

...A Case Write Up – Metabical Case Q1. Upon careful analysis of the case study we can summarise the current standing of the Metabical as a snapshot using the 5 Cs before deep-diving into the specific questions posed as follows: A. CUSTOMER: Metabical is a unique prescribed drug for overweight individuals with a BMI of 25 to 30. Essentially this group makes for our customers and consumers. More details of the target segment will follow as we discuss the case B. COMPANY: Metabical is wholly owned by by Cambridge Sciences Pharmaceuticals (CSI) an international pharmaceutical company of repute with a turnover of 25 billion dollars in 2007. C. COMPETITERS: The health and weight loss industry is cluttered with various weight loss drug options available - both prescribed and OTC, herbal remedies and dietary supplements. Meal and diet plans, exercise regimes and weight loss programmes also form the competitive landscape. D. COLLABORATORS: Doctors who prescribe the drug are influencers and we enlist them as our partners and collaborators E. CONTEXT: United States (the market) has an alarming percentage of excess weight population – 65% across ages. It is also a fairly mature market where there is high awareness for weight loss remedies. In fact, the weight loss drug industry is also tarnished by some deceptive media campaigns. There is however a defined need gap for a FDA approved prescribed drug......

Words: 252 - Pages: 2

Metabical

...Case Background Cambridge Science Pharmaceuticals (CSP) is an international health care company that develops, manufactures and markets products that treat metabolic disorders, gastrointestinal diseases, immune deficiencies and other chronic and acute medical conditions. In April of 2008, CSP’s latest product Metabical, which was a new drug that had been clinically proven to be effective at achieving weight-loss in moderately overweight individuals, had just received FDA approval as the first prescriptive drug of its kind. At the time of Metabical’s FDA approval, the only other prescription drug approved by the FDA for treating overweight individuals was Orlistat, which blocks the body’s absorption of fat; however, Orlistat has many undesirable side effects which may lead to serious medical conditions. Metabical, on the other hand, has a less dangerous, dual layer, controlled-release formulation which acts as an appetite suppressant and also contains a fat blocker as well as a calorie absorption agent. During its clinical trials, Metabical did not exhibit many of negative side effects that Orlistat has, leading to judgments that it is a superior treatment for achieving weight-loss and resulting in strong endorsements from the medical community. Weight-loss supplements can be classified as either prescriptive drugs or over-the-counter (OTC) remedies, and in general, OTC remedies are not as popular with consumers as prescription drugs for stimulating weight-loss in......

Words: 3150 - Pages: 13

Metabical

...METABICAL CASE STUDY REPORT INTRODUCTION Excess weight had become a big crisis in the US, affecting about 65% of the adult population leading to different kinds of health complications. In the past, several manufacturers had introduced various weight loss products like over-the-counter (OTC) drugs, herbal products, supplementary fad diets, etc. All of these have proven to be unsuccessful because of their ineffectiveness, severe side effects and lack of credibility among consumers. At this juncture, Barbara Printup, the Senior Marketing Director of Cambridge Sciences Pharmaceuticals (CSP) wants to introduce CSP’s newest revolutionary prescription drug, Metabical. It is the only FDA approved prescription drug for overweight people, which has minimal side effects and long term benefits. PURCHASING DECISION MAKING PROCESS (Q1) The communication strategy of Metabical targets both the health care provider and the consumer. Depending on the initiators there are two different purchase decision processes in the purchase of Metabical for the overweight problem. 1. For Customer: a. Problem identification: The various health awareness programs, BMI table etc help a health conscious or beauty conscious individual to identify the overweight problem. b. Information search: Once the problem is identified the individual decides on the course of action. He/She may decide to either ignore the problem or work on it. Metabical is interested in the group of individuals who are ready......

Words: 4420 - Pages: 18